NCT05511779View on ClinicalTrials.gov

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

April 13, 2023

Study Completion Date

April 13, 2023

Conditions
BK Virus InfectionNephropathyKidney Transplantation
Interventions
DRUG

Brincidofovir

BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours

Trial Locations (1)

Unknown

Research Site, Tokyo

Sponsors
All Listed Sponsors
lead

SymBio Pharmaceuticals

INDUSTRY